Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Invivo Therapeutics Holdings Corp    NVIV

INVIVO THERAPEUTICS HOLDINGS CORP (NVIV)
My previous session
Most popular
  Report  
SummaryChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news
The feature you requested does not exist. However, we suggest the following feature:

INVIVO THERAPEUTICS HOLDINGS CORP. : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/16/2018 | 05:18pm EST

Item 3.03. Material Modification to Rights of Security Holders.

On April 16, 2018, InVivo Therapeutics Holdings Corp. (the "Company") effected a reverse stock split of the Company's common stock, par value $0.00001 per share (the "Common Stock"), at a ratio of 1-for-25 (the "Reverse Split"). As a result of the Reverse Split, every 25 shares of the issued and outstanding Common Stock were automatically converted into one newly issued and outstanding share of Common Stock, without any change in the par value per share. Any fractional shares resulting from the Reverse Split have been rounded up to the nearest whole share. In connection with the Reverse Split, the Company correspondingly reduced the number of shares of authorized shares of Common Stock from 100,000,000 to 4,000,000.

As previously disclosed, the Board of Directors of the Company approved the Reverse Split on April 3, 2018. On April 13, 2018, the Company filed a Certificate of Change to effect the Reverse Split pursuant to Nevada Revised Statutes Sections 78.207 and 78.209 with the Secretary of State of the State of Nevada. Under Nevada law, the Company's Articles of Incorporation were deemed amended at the effective time of the Reverse Split, 5:00 p.m. Eastern Time on April 16, 2018.


Item 5.03.    Amendments to Articles of Incorporation or Bylaws; Change in
Fiscal Year.


The information set forth in Item 3.03 of this Current Report on Form 8-K is incorporated by reference into this Item 5.03. A copy of the Certificate of Change is filed as Exhibit 3.1 to this Current Report on Form 8-K.


Item 9.01.    Financial Statements and Exhibits.



Exhibit No.                                 Description
3.1              Certificate of Change Pursuant to NRS 78.209 filed with the Nevada
               Secretary of State, dated April 13, 2018.




                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INVIVO THERAPEUTICS HOLDIN
01/14INVIVO THERAPEUTICS HOLDINGS CORP. : Change in Directors or Principal Officers, ..
AQ
01/04INVIVO THERAPEUTICS HOLDINGS CORP. : Regulation FD Disclosure, Other Events (for..
AQ
2018INVIVO THERAPEUTICS HOLDINGS CORP. : Change in Directors or Principal Officers (..
AQ
2018INVIVO THERAPEUTICS HOLDINGS CORP. : Change in Directors or Principal Officers (..
AQ
2018INVIVO THERAPEUTICS HOLDINGS CORP. : Other Events (form 8-K)
AQ
2018INVIVO : 3Q Earnings Snapshot
AQ
2018INVIVO THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
2018INVIVO THERAPEUTICS HOLDINGS CORP. : Change in Directors or Principal Officers, ..
AQ
2018INVIVO THERAPEUTICS : Announces Joint Research Collaboration with Q Therapeutics..
AQ
2018INVIVO THERAPEUTICS : Announces Publication of Neuro-Spinal Scaffold Preclinical..
AQ
More news
Financials ($)
Sales 2018 -
EBIT 2018 -12,5 M
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 0
Capi. / Sales 2019 0
Capitalization 14,1 M
Chart INVIVO THERAPEUTICS HOLDINGS CORP
Duration : Period :
Invivo Therapeutics Holdings Corp Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus BUY
Number of Analysts 1
Average target price 6,00 $
Spread / Average Target 295%
EPS Revisions
Managers
NameTitle
Richard Toselli President, Chief Executive Officer & Director
C. Ann Merrifield Chairman
William D'Agostino Senior Vice President-Operations
Richard C. Christopher Chief Financial Officer & Treasurer
Richard John Roberts Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INVIVO THERAPEUTICS HOLDINGS CORP-51.17%14
THERMO FISHER SCIENTIFIC7.90%96 900
DANAHER CORPORATION2.92%74 583
INTUITIVE SURGICAL10.66%61 300
BOSTON SCIENTIFIC CORPORATION5.43%51 560
ILLUMINA0.79%44 632